Published in Hypertension on November 01, 1999
Pressed for time: the circadian clock and hypertension. J Appl Physiol (1985) (2009) 1.15
Obesity, physical activity, and their interaction in incident atrial fibrillation in postmenopausal women. J Am Heart Assoc (2014) 0.87
Incidence, Predictors, and Impact of Postoperative Atrial Fibrillation after Coronary Artery Bypass Grafting in Military Veterans. Tex Heart Inst J (2016) 0.81
Adrenomedullin upregulates M2-muscarinic receptors in cardiomyocytes from P19 cell line. Br J Pharmacol (2003) 0.77
A body shape index and heart rate variability in healthy indians with low body mass index. J Nutr Metab (2014) 0.75
Body mass index, abdominal fatness, fat mass and the risk of atrial fibrillation: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol (2017) 0.75
Review Of Obesity And Atrial Fibrillation: Exploring The Paradox. J Atr Fibrillation (2015) 0.75
Prescription of drugs during pregnancy in France. Lancet (2000) 4.12
Depressed low frequency power of heart rate variability as an independent predictor of sudden death in chronic heart failure. Eur Heart J (2000) 2.70
Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation (2008) 2.38
Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J (2000) 2.24
Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology (2000) 2.10
Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain (2000) 2.06
Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database. Pharmacoepidemiol Drug Saf (2006) 1.96
Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res (1993) 1.90
Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes (2001) 1.71
Heterogeneous distribution of beta and alpha-2 adrenoceptor binding sites in human fat cells from various fat deposits: functional consequences. Eur J Clin Invest (1987) 1.43
[Serotonin syndrome in acute poisoning with antidepressive agents]. Ann Fr Anesth Reanim (1996) 1.39
Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 1.36
Alpha-adrenergic antilipolytic effect of adrenaline in human fat cells of the thigh: comparison with adrenaline responsiveness of different fat deposits. Eur J Clin Invest (1979) 1.35
Water drinking and the heart. Lancet (1999) 1.34
Antivertigo medications and drug-induced vertigo. A pharmacological review. Drugs (1995) 1.33
Perception of the risk of adverse drug reactions: differences between health professionals and non health professionals. Br J Clin Pharmacol (2002) 1.27
Sleep attacks and Parkinson's disease treatment. Lancet (2000) 1.25
Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine. Clin Neuropharmacol (1986) 1.25
The ipsilateral cerebellar hemisphere is overactive during hand movements in akinetic parkinsonian patients. Brain (1997) 1.23
Effects of hypoxia on the expression of proangiogenic factors in differentiated 3T3-F442A adipocytes. Int J Obes Relat Metab Disord (2003) 1.22
Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers. Eur J Clin Invest (1988) 1.20
Adrenergic supersensitivity in parkinsonians with orthostatic hypotension. Eur J Clin Invest (1990) 1.18
Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol (2000) 1.18
Effects of yohimbine on submaxillary salivation in dogs. Br J Pharmacol (1989) 1.15
In situ assessment of the role of the beta 1-, beta 2- and beta 3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue. Br J Pharmacol (1996) 1.14
Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord (1999) 1.14
Selective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cells. Naunyn Schmiedebergs Arch Pharmacol (1999) 1.14
Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia (2007) 1.13
Dynamic strength training improves insulin sensitivity without altering plasma levels and gene expression of adipokines in subcutaneous adipose tissue in obese men. J Clin Endocrinol Metab (2006) 1.13
Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine. Arch Neurol (1992) 1.13
Mechanism of the lipid-mobilizing effect of alpha-2 adrenergic antagonists in the dog. J Pharmacol Exp Ther (1988) 1.11
Angiogenesis in adipose tissue. Ann Endocrinol (Paris) (2002) 1.11
Abnormal ocular movements in Parkinson's disease. Evidence for involvement of dopaminergic systems. Brain (1989) 1.09
Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry (2004) 1.09
Pharmacological prospects for alpha 2-adrenoceptor antagonist therapy. Trends Pharmacol Sci (1992) 1.09
Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol (2009) 1.08
Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. Neurology (2002) 1.07
Overview of adverse reactions to nefopam: an analysis of the French Pharmacovigilance database. Fundam Clin Pharmacol (2007) 1.07
Yohimbine increases human salivary secretion. Br J Clin Pharmacol (1989) 1.07
Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. J Clin Pharm Ther (2013) 1.06
Desensitization of beta-1 and beta-2, but not beta-3, adrenoceptor-mediated lipolytic responses of adipocytes after long-term norepinephrine infusion. J Pharmacol Exp Ther (1993) 1.05
Beta-3 adrenoceptor-mediated increase in cutaneous blood flow in the dog. J Pharmacol Exp Ther (1994) 1.04
Plasma catecholamine levels and lipid mobilization induced by yohimbine in obese and non-obese women. Int J Obes (1991) 1.03
The positive chronotropic effect induced by BRL 37344 and CGP 12177, two beta-3 adrenergic agonists, does not involve cardiac beta adrenoceptors but baroreflex mechanisms. J Pharmacol Exp Ther (1992) 1.03
Lipolytic effects of conventional beta 3-adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: preliminary pharmacological evidence for a putative beta 4-adrenoceptor. Br J Pharmacol (1997) 1.03
Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain (1998) 1.03
Human fat cell beta-adrenergic receptors: beta-agonist-dependent lipolytic responses and characterization of beta-adrenergic binding sites on human fat cell membranes with highly selective beta 1-antagonists. J Lipid Res (1988) 1.02
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord (2001) 1.01
The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men. J Lipid Res (2001) 1.01
Square wave jerks in parkinsonian syndromes. J Neurol Neurosurg Psychiatry (1991) 1.01
Odorous urine in man after asparagus. Br J Clin Pharmacol (1989) 1.00
Characterization and distribution of alpha 2-adrenergic receptors in the human intestinal mucosa. J Clin Invest (1993) 1.00
Yohimbine increases submaxillary kallikrein release into the saliva in dogs: evidence for alpha 2-adrenoceptor-mediated inhibition of cholinergic pathways. Br J Pharmacol (1991) 0.99
Culture of human adipose tissue explants leads to profound alteration of adipocyte gene expression. Horm Metab Res (2003) 0.99
Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging (2001) 0.99
[Drug-induced hiccup: a review of the France pharmacologic vigilance database]. Therapie (1999) 0.99
Ambulatory blood pressure in patients with Parkinson's disease without and with orthostatic hypotension. Clin Auton Res (1992) 0.99
Perception of risk of adverse drug reactions by medical students: influence of a 1 year pharmacological course. Br J Clin Pharmacol (2007) 0.97
Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa. J Neurol Neurosurg Psychiatry (1994) 0.97
[Drug vigilance: opinion survey among residents of a university hospital]. Therapie (1995) 0.96
L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res (2001) 0.95
Fat cell alpha 2-adrenoceptors: the regulation of fat cell function and lipolysis. Endocr Rev (1995) 0.94
Analysis of patients' narratives posted on social media websites on benfluorex's (Mediator® ) withdrawal in France. J Clin Pharm Ther (2013) 0.94
L-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin Neuropharmacol (1999) 0.94
"Medicamentation" of society, non-diseases and non-medications: a point of view from social pharmacology. Eur J Clin Pharmacol (2005) 0.94
A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol (2003) 0.92
Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction (2004) 0.92
Molecular mechanisms underlying regional variations of catecholamine-induced lipolysis in rat adipocytes. Am J Physiol (1995) 0.92
Developmental remodeling and shortening of the cardiac outflow tract involves myocyte programmed cell death. Development (1998) 0.92
Adrenergic regulation of adipocyte metabolism. Hum Reprod (1997) 0.92
Drug-induced myoclonus: a French pharmacovigilance database study. Neurophysiol Clin (2007) 0.91
Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. J Neural Transm (Vienna) (2003) 0.91
Physiological regulation of NEFA availability: lipolysis pathway. Proc Nutr Soc (2004) 0.91
High expression of leptin by human bone marrow adipocytes in primary culture. FASEB J (1998) 0.91
Adrenaline but not noradrenaline is a determinant of exercise-induced lipid mobilization in human subcutaneous adipose tissue. J Physiol (2009) 0.91
Alpha-adrenolytic properties of bromocriptine in dogs. Arch Int Pharmacodyn Ther (1982) 0.91
Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord (1994) 0.91